Some scientific research about (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal

Do you like my blog? If you like, you can also browse other articles about this kind. Application In Synthesis of (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal. Thanks for taking the time to read the blog about 499-40-1

In an article, published in an article, once mentioned the application of 499-40-1, Name is (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal,molecular formula is C12H22O11, is a conventional compound. this article was the specific content is as follows.Application In Synthesis of (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal

Cytotoxicity of cationic (NHC)Cu(I)complexes bearing 2,2?-dipyridylamine (dpa)type ligands has been evaluated toward 4 cancer cell lines, and compared to the one of neutral (NHC)Cu(I)complexes. The high cytotoxicity of these novel cationic (NHC)Cu(I)complexes, combined with the straightforward synthesis, and versatility of dpa type ligands may offer new prospects in cancer research, toward the development of novel carrier linked prodrugs.

Do you like my blog? If you like, you can also browse other articles about this kind. Application In Synthesis of (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal. Thanks for taking the time to read the blog about 499-40-1

Reference:
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics